Stanley Riddell

Stanley Riddell
Seattle (USA)


Stanley Riddell is a Full Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC), Professor of Oncology at the University of Washington School of Medicine, and also Scientific Co-Founder of Juno Therapeutics Inc. Dr. Riddell is a leader in developing therapies that harness the immune system to fight cancer and infectious diseases. His research led to patented technologies that rapidly expand the number of disease fighting T cells used in adoptive immunotherapy. Findings from Dr. Riddell’s laboratory have led to multiple clinical trials, including the first human trial of CD19 CAR-T cells of defined T cell subset composition.

Dr. Riddell was recently elected to the Association of American Physicians, an organization honoring those who have achieved excellence in biomedical science. He is the recipient of ASCO Young Investigator Award and the Cancer Research Institute Partridge Foundation Investigator Award. In 2010, Dr. Riddell received the International Society for Biological Therapy of Cancer’s first Team Science Award for major contributions to research and the clinical translation of cancer immunotherapy, and in 2016 was named an American Cancer Society Research Professor. Dr. Riddell earned his M.D. at University of Manitoba and is a Board Certified Medical Oncologist.

Latest News


Workshop Registration for HFYLS 5 paticipants is possible from now on. Places are limited and will be assigned on a first-come-first-serve basis.




Join us now on